> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncologic Drugs Panel Meeting to Review Amgen sBLA
- URL: https://www.fdaweb.com/oncologic-drugs-panel-meeting-to-review-amgen-sbla/
- Published: 2018-02-15T12:00:00.000Z
- Updated: 2026-09-14T23:23:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140768

*Federal Register* notice: FDA has announced a 3/7 Oncologic Drugs Advisory Committee meeting. Panel members are scheduled to discuss an Amgen supplemental BLA for Blincyto (blinatumomab) injection for intravenous use, indicated for treating minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-02-15/pdf/2018-03174.pdf?ref=fdaweb.com).